Table 1.
Patient Characteristics
| Characteristic | Patients (n = 15) |
|---|---|
| Median age, y | 37 |
| Male sex, n (%) | 9 (60) |
| Race/ethnicity, n (%)1 | |
| Asian/Pacific Islander | 4 (27) |
| Black/African American | 2 (13) |
| Caucasian | 5 (33) |
| Hispanic | 4 (27) |
| Duration of psoriasis, y | 15 (±10) |
| PASI score | 20.8 ± 13.4 |
| PGA score, n (%) | |
| 3 | 3 (20) |
| 4 | 9 (60) |
| 5 | 3 (20) |
| Psoriatic arthritis, n (%) | 1 (7) |
| Family history of psoriasis, n (%) | 5 (33) |
| Previous treatment, n (%) | |
| Topical therapy only | 2 (13) |
| Phototherapy2 | 9 (60) |
| Conventional systemic therapy3 | 5 (33) |
| Biologic agent | 9 (60%) |
Abbreviation: PGA, Physician’s Global Assessment; y, year.
PASI scores range from 0 to 72, with higher scores indicative of more severe disease. PGA evaluates psoriasis on a scale from 0 to 5, with 0 indicating cleared psoriasis, 1 indicating minimal psoriasis, 2 indicating mild psoriasis, 3 indicating moderate psoriasis, 4 indicating marked psoriasis, and 5 indicating severe psoriasis. Plus‒minus values are the SDs from the mean.
1
Race was self-reported.
2
Phototherapy included UVB therapy and psoralen plus UVA therapy.
3
Conventional systemic therapies include methotrexate, acitretin, and cyclosporine.